XNW4107, IMIPENEM, CILASTATIN, RECARBRIO clinical trials

A Multicenter, Randomized, Double-Blind, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin-XNW4107 in Comparison with Imipenem/Cilastatin/Relebactam in Adults with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia

This study looks at new treatments for severe lung infections caught in hospital, like pneumonia. It compares a new medicine (XNW4107) with an existing one (Recarbrio) to see which is safer and more effective at helping patients recover and survive.